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Hedgehog (HH)-GLI signaling is a developmental patterning pathway used by many tumors for bulk prolifer-
ation that has been shown also to regulate cancer stem cell self-renewal and survival. Surprisingly, a recent
study by Yauch et al. (2008) proposes that HH-GLI signaling acts only on the tumor stroma. The mode of ac-
tion of HH-GLI signaling in cancer may shape the development of therapeutic antagonists.Cancer Cell 14, October 7, 2008 ª2008 Elsevier Inc. 281Intercellular patterning signaling path-
ways involved in organizing the body
plan in the embryo, including Hedgehog
(HH), Wnt, and Notch, have been identi-
fied as key players in human cancers.
The mechanisms of their actions in normal
and pathological conditions are under in-
tensive investigation, as this knowledge
may lead to not only an understanding of
tumor ontogeny (and therefore of devel-
opmental plasticity) but also the design
of new therapies. This is of great signifi-
cance, as these pathways participate in
incurable metastatic cancers.
A milestone in understanding cancer as
a developmental problem is the identifica-
tion of cancer stem cells that self-renew,
give rise to the tumor bulk, and reinitiate
tumor development. Standard chemo-
and radiotherapies can greatly reduce tu-
mor bulk but may be less effective on can-
cer stem cells, which may induce cancer
recurrence. The key challenge has been
in identifying the molecular mechanisms
that maintain and support cancer stem
cell self-renewal and survival.
HH-GLI signaling (Figure 1A), one of the
most critical pathways in animal pattern-
ing, has been implicated in several unre-
lated sporadic human cancers, including
cancers of the skin, brain, prostate, stom-
ach, pancreas, and lung. As these organs
are unrelated in developmental origin,
site, or function, a common dependence
of cancer stem cells on HH-GLI signaling
for survival and self-renewal, paralleling
its roles in normal development and ho-
meostasis, could underlie its widespread
involvement in human cancers.
Direct evidence that HH-GLI signaling
has a critical role in cancer stem cells de-rives from a number of recent studies in
different tumor types (Figure 1B). In glio-
blastoma multiforme (GBM), self-renewal
and survival of clonal gliomasphere-
forming cells depend on SMOOTHENED
(SMOH) and GLI1 activities, as tested by
inhibition with the natural small molecule
cyclopamine, a specific SMOH inhibitor,
and interference with siRNAs (Clement
et al., 2007; Bar et al., 2007). GBM stem
cell cultures respond to cyclopamine
and exogenous Sonic hedgehog (SHH)
ligand by downregulating or upregulating
GLI1 transcription (which marks a cell’s
response to HH pathway activity), respec-
tively. The growth of gliomasphere-de-
rived intracranial GBMs is greatly reduced
by systemic treatment with cyclopamine
or the conditional activation of SMOH
by lentiviral-mediated RNA interference
(Clement et al., 2007). These effects are
specific, as the inhibitory activity of
shRNAs against SMOH and of cyclo-
pamine are rescued by GLI1, consistent
with their epistatic relationship in the HH
pathway (Figure 1A). CD133+ GBM can-
cer stem cells express GLI1 and display
a HH-GLI-responsive stemness signature
that includes NANOG, SOX2, OCT4, and
BMI1 (Clement et al., 2007).
HH-GLI signaling also appears to be
active in CD44+CD24/lowLin putative
breast cancer stem cells, as these
express GLI1 (Liu et al., 2006), and treat-
ments with cyclopamine or anti-HH block-
ing antibody reduce the clonogenicity of
CD19+CD37+ multiple myeloma cancer
stem cells (Peacock et al., 2007).
Sources of HH ligands include CD133+
cancer stem cells and tumor-induced
vasculature in GBMs (Clement et al.,2007) and the stroma in lymphomas
and multiple myelomas (Dierks et al.,
2007).
Given the results summarized above,
the proposed effect of tumor-derived
HH only on surrounding stroma reported
by Yauch et al. (2008) is intriguing
(Figure 1C). Yauch et al. show that tumor
cells expressing HH can induce a re-
sponse in adjacent stromal cells and re-
port that treatment of human xenografts
of such cancers, including those of the
prostate, pancreas, and ovary, with cy-
clopamine or another blocker of SMOH
(HhAntag) does not lead to significant
tumor regression at doses that affect
GLI-dependent luciferase reporter activ-
ity. They then document a response to
SMOH blockers in the mouse stromal
compartment, but not in human epithelial
cells, and show that SMOH-dependent
functions in stroma are required for xeno-
graft growth. Thus, unlike the reported in-
hibition of epithelial tumor growth by
blocking HH-GLI signaling in cancers
with detectable cell-autonomous path-
way-activating mutations (e.g., basal cell
carcinoma), Yauch et al. do not detect
inhibition of epithelial cells by HH-GLI
pathway blockade in HH ligand-depen-
dent tumors and conclude that this path-
way acts only on the stroma.
These are interesting results that raise
three important issues:
(1) The reported lack of response by
epithelial tumor cells to HH-GLI
modulation contrasts with exten-
sive data from several laboratories
with cell lines and patient-derived
primary cultures of melanomas
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lung cancers, among others, using
recombinant SHH, anti-HH block-
ing antibodies, cyclopamine, and
siRNAs (e.g., Dahmane et al.,
2001; Thayer et al., 2003; Sanchez
et al., 2004; Karhadkar et al., 2004;
Stecca et al., 2007). While Yauch
et al. (2008) did not observe a cor-
relation of cyclopamine action with
GLI1 or PTCH1 downregulation,
their assays may have been per-
formed too late (24 hr after treat-
ment) for detection of such a re-
sponse, in contrast to previous
studies where cyclopamine clearly
downregulated GLI1 and PTCH1
4 hr posttreatment followed by
recovery (Clement et al., 2007;
Stecca et al., 2007; B. Stecca,
F. Varnat, and A.R.A., unpublished
data). Their xenograft results also
differ from prior studies that in-
cluded rescue by expression of
GLI1 and conditional interference
of SMOH in epithelial tumor cells
(e.g., Karhadkar et al., 2004; Clem-
ent et al., 2007; Dierks et al., 2007).
The reasons for these discrep-
ancies are unknown. Different re-
sponse kinetics of stromal versus
epithelial cells could partly explain
the results. Nevertheless, whereas
pharmacological treatments can
affect multiple cell types, lentivi-
ral-mediated silencing of SMOH
only in epithelial cells is efficient in
inhibiting the growth of intracranial
and subcutaneous GBMs and
subcutaneous melanoma xeno-
grafts (Clement et al., 2007; Stecca
et al., 2007), demonstrating the re-
quirement of HH-GLI in epithelial
tumor cells.
(2) Yauch et al. demonstrate a para-
crine action from HH ligand-ex-
pressing epithelial cells on sur-
rounding mouse stroma. This is
interesting and reinforces the criti-
cal role of the stromal microenvi-
ronment on epithelial tumor
growth. Caution is required, how-
ever, regarding the extension of
such data to the human stroma,
as this is quickly replaced by its
mouse counterpart in patient-de-
rived tumor xenografts (Yauch
et al., 2008). Moreover, detailed
in situ hybridization analysis of82 Cancer Cell 14, October 7, 2008 ª2008human tissue suggests autocrine
signaling, as the prostate epithe-
lium is the site of robust SHH and
GLI1 expression, and PSA+ pros-
tate cancer epithelial cells respond
to exogenous SHH and anti-HH
blocking antibodies and cease
Figure 1. Modulations and Modes of Action
of HH-GLI Signaling in Cancer
(A) Schematic diagram of HH-GLI signaling, with
the action of inhibitors noted. Regulation of the
GLI transcription factors occurs in the primary cil-
ium before they enter the nucleus and regulate
gene expression.
(B–D) Diagrams of the different possible modes of
action of HH signaling in cancer stem cells and on
the tumor bulk (B), on stromal cells only (C), or on
both epithelium and stroma (D).Elsevier Inc.proliferation in response to cyclo-
pamine treatment (Sanchez et al.,
2004). Human metastatic melano-
mas also strongly coexpress SHH,
GLI1, and PTCH1 in epithelial
tumor cells and not in the surround-
ing stroma (Stecca et al., 2007). In
contrast, rodents display paracrine
Hh signaling from the prostate
epithelium to the mesenchyme
(Pu et al., 2004). Whether HH-GLI
affects the stroma of human tumors
in addition to the epithelium and its
cancer stem cells (Figure 1D) re-
quires investigation.
(3) The new SMOH blocker used by
Yauch et al. appears limited in its
efficacy. Administration of their
proprietary SMOH blocker HhAn-
tag reduced tumor volume by
20%–50% after 20 days, which
contrasts with the eradication of
engrafted human melanomas and
prevention of their recurrence by
local cyclopamine treatment for
20 days, and with the elimination
of their metastatic growth in the
lungs by systemic cyclopamine
treatment (Stecca et al., 2007).
Methodological differences could
explain the varying results, as
systemic (intraperitoneal) cyclo-
pamine treatment also has limited
effects on subcutaneous xenograft
growth (reducing it by 30%),
likely due to inefficient drug deliv-
ery (Stecca et al., 2007). However,
if blocking HH-GLI signaling were
to affect only the stroma and have
limited effects, the development
of antagonists for many kinds of
devastating cancers could lack
support. On the contrary, the ac-
tion of HH-GLI on cancer stem
cells provides a solid basis for the
development of better antagonists,
independent of whether they also
act on the stroma.
Cancers harbor many mutations, but
they appear to be fully dependent on the
inappropriate activity of a few develop-
mental pathways. Elucidating the mecha-
nisms by which HH-GLI signaling regu-
lates cancer stem cell self-renewal and
survival, and extending the current find-
ings to additional cancer types, should
pave the way for new rational and specific
drugs to treat presently incurable
Cancer Cell
Previewscancers. The evidence is promising, and
the possibilities wide open.
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of origin as well as the spectrum of so-
matic alterations (mutations and promoter
methylation events) sustained by its lineal
descendants within a primary tumor are
both likely to affect the probability of
evolving highly malignant cell traits (Ber-
nards and Weinberg, 2002; Ince et al.,
2007). In addition, the stromal microenvi-
ronment of a primary carcinoma is also
likely to contribute heterotypic signals
that influence the eventual development
of invasive traits (Bhowmick et al., 2004).
Once these various factors converge on
individual tumor cells and impart to them
an invasive phenotype, these cells may
gain ready access to the systemic circula-
tion, providing them with channels that
carry them to distant sites in the body.
More often than not, the destination sites
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ys that are very different from those
are likely to be dictated by the accidental
trapping of relatively large cancer cells in
the small-diameter microvessels present
in most organs. The lung is a favored
site of initial dissemination, as its capillary
bed is the first encountered by circulating
tumor cells after they have entered into
the venous circulation and made an initial
pass through the heart.
Most cells (>95%) are cleared from sites
of initial trapping in the lungs (for example)
within a day or two. Moreover, the fate of
the survivors that succeed in extravasating
is hardly clear. Some may survive as indo-
lentmicrometastases for extendedperiods
of time without losing their viability, while
most eventually disappear. Only on very
rare occasions do the cells in micrometa-
stases succeed in proliferating vigorously
and forming a macroscopic metastasis—
the colonization process (Fidler, 2003).
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